Skip to main content
Clinical Trials/CTRI/2022/01/039493
CTRI/2022/01/039493
Completed
Phase 4

Clinical Study to assess the Efficacy and Safety of Haridradya Taila in Acne and Acne-induced Post-inflammatory Hyperpigmentation

Ms Ozone Pharmaceuticals Ltd0 sites50 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Ms Ozone Pharmaceuticals Ltd
Enrollment
50
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
May 31, 2022
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Ms Ozone Pharmaceuticals Ltd

Eligibility Criteria

Inclusion Criteria

  • Patients of either sex having mild to moderate facial Acne and mild to moderate acne induced PIH in clinical features.
  • ïâ??· Patients of age between 18 \- 45 years.
  • ïâ??· Willing to take part in study and signing consent form

Exclusion Criteria

  • 1\. With Present History of Skin Disease e.g. Psoriasis, Dermatitis, Vitiligo etc. related to face.
  • 2\. Person suffering from any infective or contagious skin disease
  • 3\. Under medication with antibiotics, antifungal and steroid during last one month.
  • 4\. Women on Oral contraceptives
  • 5\. Patients of known uncontrolled hormonal disease.
  • 6\. Any kind of diagnosed hereditary skin disorder.
  • 7\. Patient who had undergone any type of skin treatment like laser therapy in last 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials